Introduction {#S5}
============

The use of economic simulation modeling tools to support decision making in the health care setting is widespread and necessary \[[@R1],[@R2]\]. This is especially true for chronic and progressive diseases such as diabetes mellitus (DM), for which the time horizon of interest for decision making is lifetime and thus beyond the time and resource constraints of clinical trials. Health economic modeling provides a unique opportunity to capture the health and cost consequences of new interventions over the relevant time horizon as well as across all comparators of interest to decision makers.

To inform the allocation of resources, models informing such decisions must be clinically credible and valid for the populations and jurisdictions of interest. This can be achieved by reporting models in a transparent manner and testing their internal and external validity. This was emphasized in the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making (ISPOR-SMDM) Modeling Good Research Practices \[[@R2]\], which advocated for "sufficient information to enable the full spectrum of readers to understand a model's accuracy, limitations, and potential applications at a level appropriate to their expertise and needs" \[[@R3]\], and in the DM-specific American Diabetes Association (ADA) guidelines for computer modeling \[[@R4]\], which encouraged reporting "in sufficient detail to reproduce the model and its results" \[[@R4]\]. The Second Panel on Cost-Effectiveness in Health and Medicine \[[@R5]\] similarly advocated transparency, although in a more limited manner.

The main focus of these guidelines is on the transparency of model structure, rather than on the assumptions and data used in simulating an individual application (e.g., population characteristics at baseline and the assumed nature and duration of treatment effects). A model with a fully transparent (and internally and externally valid) structure is not sufficient to reproduce the results of any individual simulation. To achieve this, one must also know what assumptions and input data were included. In the spirit of the Turing test \[[@R6]\] of a machine's ability to exhibit intelligent behavior, we have constructed a hypothetical thought experiment in which two isolated users have access to the same computer simulation model. Awas inadequately transparent simulation would be regarded as transparent if one of the users was able to produce a set of instructions of the simulation they undertook that was sufficiently detailed and comprehensive to allow the other user to implement them and produce identical results using the same model. The ISPOR Consolidated Health Economic Evaluation Reporting Standards checklist \[[@R7]\] outlines many of the items that should routinely be in an economic evaluation, and the Philips checklist is a best practice guideline in model reporting \[[@R8]\]. Both include a range of items concerning application-specific input data. They may, however, be overly general to satisfy the needs in complicated multifactorial disease areas such as DM, and so we have attempted to address this gap in the literature using the Mount Hood diabetes simulation modeling network.

Initiated in 2000 by Andrew Palmer and Jonathan Brown at Timberline Lodge, Mount Hood, OR \[[@R9]--[@R11]\], the Mount Hood Challenge is a biennial congress in which as many as 10 DM modeling groups have met to compare and contrast models, methods, and data in the context of simulating standardized treatment scenarios and discussing the results. In September 2016, DM modeling groups gathered in St. Gallen, Switzerland, for the Eighth Mount Hood Challenge, with the aim of standardizing the recording and documentation of simulation inputs and communication of outputs in DM simulation modeling and thereby promoting transparency.

Specifically, the aims of the 2016 Mount Hood Challenge were twofold:

1.  to evaluate transparency of key model inputs using two published studies as examples; and

2.  to develop a DM-specific checklist for transparency of input data that can be used alongside general health economic modeling guidelines to improve reproducibility of health economic analyses in DM.

The present article summarizes the findings from the first objective and how modelers built on these to develop a series of DM-specific transparency recommendations addressing the second aim. The resulting checklist can serve as a means of improving consistency and transparency in diabetes simulation models and provide a framework for developing similar standards in other disease areas.

Methods {#S6}
=======

The Eighth Mount Hood Challenge was advertised on the Mount Hood Challenge Web site (<https://www.mthooddiabeteschallenge.com/>) and all known published diabetes modeling groups were invited to participate. The meeting featured two exercises using instructions provided before the meeting: a transparency challenge on day 1 and a communicating outcomes challenge on day 2. Modeling groups were encouraged to submit results for both challenges. Over the course of 2 days, results were presented and discussed, and paths to improvement were debated. A representative from each of the modeling groups was invited to participate on the third day to choose a topic for a meeting proceedings article. The group chose to focus this article on the transparency challenge only. For details of methods and results of the communicating outcomes challenge, interested readers are referred to the Mount Hood Challenge Web site \[[@R12]\].

The Transparency Challenge {#S7}
--------------------------

Model transparency, "the extent to which interested parties can review a model's structure, equations, parameter values, and assumptions" \[[@R3]\], is often poor in published economic evaluations, particularly for complex diseases such as DM \[[@R4]\]. More than 10 years after the ADA guidelines promoted increased transparency, this is the first time diabetes modeling groups have attempted to answer the questions "How reproducible are published simulation modeling studies?" and "What is the best way to describe a simulation so that it can be reproduced?"

The modeling groups were assigned two preselected published economic modeling studies in DM \[[@R13],[@R14]\] (see instructions in [Appendix 1 in Supplemental Materials](#SD1){ref-type="supplementary-material"} found at <https://doi.org/10.1016/j.jval.2018.02.002>). The first transparency challenge was to replicate the Baxter et al. \[[@R13]\] study, which used the IQVIA-Core Diabetes Model (IQVIA-CDM) to estimate the impact of modest and achievable improvements in glycemic controls on cumulative incidences of microvascular and macrovascular complications and the costs in adults with type 1 (T1DM) or type 2 DM (T2DM) in the UK system \[[@R13]\]. This transparency challenge focused on simulating the T2DM results.

The second transparency challenge was to replicate the UK Prospective Diabetes Study 72 (UKPDS 72), which used the UKPDS Outcomes Model (UKPDS-OM) version 1 to evaluate the cost utility of intensive blood glucose (conventional vs. intensive blood glucose control with insulin or sulphonylureas, and conventional vs. intensive blood glucose control with metformin in overweight patients) and blood pressure control (less tight blood pressure control vs. tight blood pressure control with angiotensin-converting enzyme inhibitors or β-blockers in hypertensive patients) in T2DM \[[@R14]\]. This transparency challenge focused on the comparison of intensive versus conventional blood glucose control in the main randomization.

Modeling groups were asked to use data provided in the study publications including supplementary appendices \[[@R13]\] as inputs into their models and replicate the study analyses. When critical data could not be found in the study publication, they were asked to record assumptions required to fill those data gaps. Simulation results were not blinded. Each group submitted results in advance of the congress.

The data gaps reported by each group were summarized in a tabular format and compared and contrasted during meeting proceedings. Detailed results for costs and cumulative incidences were presented in tables by each model group for each challenge. Agreement between the replicated and original study results was evaluated using scatterplots.

Results {#S8}
=======

Short biographies of the 10 modeling groups that participated in the Eighth Mount Hood Challenge can be found in [Appendix 2 in Supplemental Materials](#SD2){ref-type="supplementary-material"} found at <https://doi.org/10.1016/j.jval.2018.02.002>. This article reports results of the modeling groups that submitted simulation results for the transparency challenges and who agreed to publication in this journal. It should be noted that other modeling groups were involved in the Eighth Mount Hood Challenge and results for the communicating outcomes challenges can be found on the Mount Hood Challenge Web site \[[@R12]\]. Groups were asked to document all their assumptions made in the transparency challenges. These were detailed in the meeting program, also available from the Mount Hood Challenge Web site \[[@R15]\].

Transparency Challenge 1: Reproducing Baxter et al. \[[@R13]\] {#S9}
--------------------------------------------------------------

Five modeling groups participated in the Baxter challenge: the Cardiff model, the Economics and Health Outcomes Model of T2DM (ECHO-T2DM), the Medical Decision Modeling Inc.---Treatment Transitions Model (MDM-TTM), the Michigan Model for Diabetes (MMD) model, and the IQVIA-CDM. All groups presented simulation results with the exception of the MMD group, which submitted only a document summarizing identified input data gaps. The necessary input data that were not found in the study publications as reported by modeling groups are summarized in [Appendix 3 in Supplemental Materials](#SD3){ref-type="supplementary-material"} found at <http://doi.org/10.1016/j.jvaL.2018.02.002>, along with assumptions made and alternative data sources used to fill these gaps. All modeling groups documented a lack of transparency in reporting model inputs in the Baxter study, including important deficiencies such as baseline patient characteristics, treatment effects, and glycated hemoglobin (HbA~1c~) evolution, thereby forcing modeling groups to make a host of assumptions to fill these gaps. These assumptions differed between groups and contributed to the diverse results. For example, for effect evolution, the Cardiff modeling group assumed that HbA~1c~ was maintained at 7.5% when patients reached this level and the comparator group followed a natural HbA~1c~ progression. The ECHO-T2DM group assumed no evolution in HbA~1c~ or other biomarkers, the IQVIA-CDM modeling group used data from UKPDS 68 for HbA1c evolution \[[@R16]\], and the MDM-TTM modeling group used its default treatment regimen.

Results of the replication analyses from each modeling group and the original study results are presented in [Table 1](#T1){ref-type="table"} for the cost reductions and in [Table 2](#T2){ref-type="table"} for the number of complications avoided, over time and by baseline HbA~1c~ subgroup. None of the model results consistently matched the Baxter et al. study results, including the replication using the same IQVIA-CDM underlying the Baxter et al. study results (but without access to unpublished parameters). The scatterplots, shown in [Figure 1](#F1){ref-type="fig"}, confirm discordance between replicated and original results. The IQVIA-CDM modeling group generally overestimated the cost reductions, and other modeling groups generally under-estimated the cost reductions, yielding a best-fitting regression line (intercept suppressed) that indicates general underprediction (slope = 0.71), with an *R*^2^ of 0.52. The fit for number of complications avoided is similarly underestimated with an *R*^2^ of 0.35.

Transparency Challenge 2: Reproducing UKPDS 72 \[[@R14]\] {#S10}
---------------------------------------------------------

Seven modeling groups participated in the UKPDS 72 challenge and consented to publication: the Cardiff model, the ECHO-T2DM model, the MDM-TTM, the Modelling Integrated Care for Diabetes based on Observational data model, the MMD model, the IQVIA-CDM, and the UKPDS-OM (versions 1 and 2). All groups presented their challenge results except for the MMD group. Of note, both UKPDS-OM versions 1 and 2 participated in this exercise, providing an interesting contrast. UKPDS-OM version 1 was used in the UKPDS 72 study, and so provided a clean test of how reproducible the results are from the inputs provided in the publication, whereas the results from UKPDS-OM version 2 provided a further examination of how much the newer equations differ in estimates of health and risk in a controlled environment. The necessary input data that were not found in the study publications as reported by modeling groups, along with their assumptions and alternative data sources used to fill these gaps, are documented in [Appendix 4 in Supplemental Materials](#SD4){ref-type="supplementary-material"} found at <https://doi.org/10.1016/j.jval.2018.02.002>. All modeling groups identified gaps in the reporting of UKPDS 72, including absence of information on baseline patient characteristics, initial treatment effects, HbA~1c~ evolution, and treatment use over time. Modeling groups generally sourced missing information from other UKPDS publications, however, with presumably little bias. For example, all groups sourced baseline characteristics from UKPDS 33 \[[@R17]\]. Different assumptions regarding treatment effects, risk factor progression, and unit costs were used.

Results of the replication analyses for each modeling group and the original study results are presented in [Table 3](#T3){ref-type="table"}. The Cardiff model most closely estimated costs; the IQVIA-CDM overestimated costs and the other models underestimated costs. In general, there was a good agreement of quality-adjusted life-years (QALYs) between the replicated and the original study results, although lifetime QALYs estimated by the Modelling Integrated Care for Diabetes based on Observational data model were considerably lower than those reported in UKPDS 72. The scatterplots ([Fig. 2](#F2){ref-type="fig"}) confirm good agreement in results on QALYs, but not on costs, although the *R*^2^ values were high in both cases (QALYs 0.97, costs 0.89).

The Diabetes Modeling Input Checklist {#S11}
-------------------------------------

The representatives of the modeling groups met on the morning of September 19, 2016, to translate the findings of the transparency challenge into recommendations for improved simulation input data reporting. The Diabetes Modeling Input Checklist was developed with the intention that it should be used for future publications of long-term modeling economic evaluations in diabetes and possibly to be adopted by journals when reviewing submissions. The representatives agreed on the following:

1.  There are glaring omissions in the documentation of inputs in published studies (not just the two examples considered in the challenges) that limit reproducibility. The possible reasons are multiple, including publication word limit, lack of thoroughness, and intentional lack of transparency.

2.  Existing checklists \[[@R3],[@R7],[@R18]\] are general and inadequate for informing fully transparent reporting for complex DM simulation modeling with its extreme input data burden.

3.  There is a need for a DM-specific checklist.

4.  Ideally, a DM-specific checklist should be simple (specifying a minimum required amount of information) and complement (not supersede) existing guidelines.

5.  A general consensus should be formed on the specific input items for DM models that should be included in the checklist (note that this did not include a discussion about what numerical values for input may or may not be best).

The Diabetes Modeling Input Checklist is presented in [Table 4](#T4){ref-type="table"} and the main summary is given herein.

Simulation Cohort {#S12}
-----------------

Baseline patient characteristics of the simulated cohort should be clearly stated, including age, sex, ethnicity/race, body mass index (BMI)/weight, duration of diabetes, baseline HbA~1c~, lipids and blood pressure levels, smoking status, comorbidities, physical activity, and baseline treatments (aspirin, statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and/or glucose-lowering treatments). Baseline characteristics should be presented in a tabular format as mean with SD or as proportion, as appropriate whenever possible. In addition, the type of distribution of the baseline characteristics should be reported in the table.

Treatment Interventions {#S13}
-----------------------

First, the chosen treatment(s) and treatment algorithm for blood glucose control or treating hypertension, dyslipidemia, excess weight, or any other relevant condition in the comparator and intervention should all be specified. Second, it is helpful to specify the initial impact of treatment(s) on baseline biomarkers. Third, it is important to state the rules for treatment intensification, for example, the threshold HbA~1c~ (or blood pressure, lipid, BMI, or estimated glomerular filtration rate \[eGFR\]) level that triggers a change in treatment and the new treatment regimen. Moreover, it should be specified whether the change in treatment is an addition or substitution to the previous treatment. Fourth, modelers should also specify in detail the set of long-term effects, adverse effects, treatment adherence and persistence, and any assumptions on legacy effects (i.e., residual treatment effects after the discontinuation of a treatment) that are considered in the model. In addition, it is helpful to describe the direct and indirect linkages between treatment effects and primary outcomes including health outcomes, costs, and effectiveness (e.g., HbA~1c~ affects stroke, myocardial infarction, retinopathy, and nephropathy risks directly, and indirectly affects mortality through its impact on events specific to cardiovascular disease and associated mortality). Finally, it is important to include the trajectory of biomarkers (e.g., HbA~1c~, lipids, blood pressure, BMI, eGFR, and smoking) and any other factors that are affected by interventions and have an impact on modeled patient health outcomes.

Costs {#S14}
-----

All state-specific and treatment-specific costs should be detailed in a separate section and may be differentiated by acute event costs in the first year and ongoing costs in subsequent years. The costs should include costs of intervention themselves as applied in the model and other costs such as adverse events, complication management, and diagnostics if applied. Complication costs should consider the timing of the event. For example, macro-vascular complications often have a high cost at the time of the event and lower follow-up management costs thereafter. If the evaluation is from the societal perspective, it should specify assumptions related to indirect costs such as foregone productivity and any other costs (e.g., transportation). Moreover, the type of productivity losses (i.e., absenteeism, presentism, or early retirement) and the methods used to evaluate productivity losses should be stated in the costs methods section.

Health State Utilities {#S15}
----------------------

Methodological approaches to estimating utility in the presence of multiple comorbidities include alternative options including the "minimum," "multiplicative," or other approaches. For example, the minimum approach uses the value of the condition with the lowest individual utility score, whereas the multiplicative approach uses the arithmetic product of utility scores as a proportion of full health. It should be clearly stated which method is used to adjust the health state utilities of multiple comorbidities.

General Model Characteristics {#S16}
-----------------------------

There are other factors that may have a substantive impact on model transparency. First, the choice of the country-specific life table for all-cause mortality should be clearly stated in the Methods section, and when a specific event-related mortality is incorporated, it must be stated. Second, it is important to document the source and details of risk equations used in the model. Finally, if using a microsimulation model, authors should report the number of Monte-Carlo simulations performed per individual simulated and justify that choice. When performing probabilistic sensitivity analysis, it is important to document and justify which components of model uncertainty are being propagated to the model outputs (e.g., risk equations, risk factor trajectories, and treatment effect), the methods and assumptions used to propagate the uncertainty, and the number of Monte-Carlo simulations used to reflect parameter uncertainty.

Discussion {#S17}
==========

ISPOR-SMDM emphasized the importance of transparency for engendering confidence and credibility for health economic decision modeling \[[@R3]\], and the ADA advocates a similar approach for diabetes modeling specifically \[[@R4]\]. The main theme of the Eighth Mount Hood Challenge was transparency and reproducibility of computer simulation models in diabetes. The transparency challenge illustrated substantial difficulties in reproducing study results using the published input data. The modeling groups responded to data gaps with widely varying assumptions, yielding large differences in some outcomes. Differences in the degree of reproducibility of the Baxter et al. \[[@R13]\] and the UKPDS 72 \[[@R14]\] studies were consistent with the comprehensiveness of inputs provided. The results indicate that substantial shortcomings remain, providing impetus for the modeling groups to jointly develop a DM-specific input reporting checklist.

A large number of inputs are required for simulation modeling in DM. Full transparency requires considerable resources of both modelers and the consumers of modeling results, which creates a "cost of transparency." The Diabetes Modeling Input Checklist represents a pragmatic approach, focusing on parameters and assumptions that are influential in typical applications. It is important to note that models may differ substantially in structure and input variables. Although some inputs may be specific to a particular model, such as the renal risk factor eGFR, it is important that modelers transparently document the assumptions made around the level and time path of that risk factor. Note, however, that additional items important to any specific application should naturally be reported even if not explicitly mentioned in the checklist. Optimizing transparency of inputs to simulation will assist in understanding the assumptions used in projections and will facilitate a better understanding of why model results may not be realized if future conditions change in an unforeseen way. In addition, with an increased use of this checklist in future health economic modeling studies, we plan to test whether this checklist increases transparency of diabetes model inputs at an upcoming Mount Hood Challenge.

This checklist is not free-standing, but should be used to complement the more general guidelines such as the ISPOR-SMDM guidelines for model transparency \[[@R3]\], the Philips guidelines \[[@R18]\], the ISPOR Consolidated Health Economic Evaluation Reporting Standards guidelines for modeling study reporting \[[@R7]\], and the ADA guidelines for modeling of diabetes and its complications \[[@R4]\]. The Mount Hood Challenge Modeling Group recommends routine use of the Diabetes Modeling Input Checklist. Modelers should document simulation inputs in line with the checklist and submit these as supplementary materials with publications. Journal editors and reviewers should permit (even require) the inclusion of the checklist with any DM-related modeling publications.

Conclusions {#S18}
===========

In previous Mount Hood Challenges, modeling groups worked together to compare outcomes for hypothetical diabetes cohorts and interventions \[[@R9]\] and to compare outcomes simulated from health economic models to those from real-world data \[[@R10],[@R11]\]. In the latest Mount Hood Challenge, the potential shortcomings of poor simulation input transparency were clearly demonstrated, leading to these consensus recommendations intended to promote transparency. Increased transparency can improve both the credibility and the clarity of model-based economic analyses. Although the checklist we propose is specific to DM, it will hopefully inspire modelers in similarly complex fields to promote transparency of model inputs to improve the reliability of model outputs.
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![Comparisons of cumulative complications avoided and cost reductions vs. the Baxter et al. \[[@R13]\] study. Each scatterplot denotes a comparison of results from the modeling groups and those from the Baxter study. The dotted line is the fitted regression line of all comparisons, and the solid line denotes hypothetical perfect agreement between values generated from the modeling groups and those from the original study, that is, *R*^2^ = 1 and line intersecting the origin (0). Overall, there is a reasonable good agreement between the results from the modeling groups and those from the Baxter study. The slopes of the regression line are 0.66 and 0.71 and the *R*^2^ are 0.35 and 0.52 for the comparisons of complications avoided and cost reductions, respectively. ECHO, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc. ---Treatment Transitions Model; IQVIA-CDM, IQVIA-Core Diabetes Model; T2DM, type 2 diabetes mellitus.](nihms-1037199-f0001){#F1}

![Comparisons of total costs and QALYs vs. the UKPDS 72 study \[[@R14]\]. Each scatterplot denotes a comparison of results from the modeling groups and those from the UKPDS 72 study. The dotted line is the fitted linear regression line, and the solid line denotes hypothetical perfect agreement between values generated from the modeling groups and those from the original study, that is, *R*^2^ = 1 and line intersecting the origin (0). Overall, there is a good agreement between the results from the modeling groups and those from the UKPDS 72 study. The slopes of the regression line are 0.75 and 0.98 and the *R*^2^ are 0.89 and 0.97 for the comparisons of total costs and QALYs, respectively. ECHO, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc.---Treatment Transitions Model; QALY, quality-adjusted life-year; IQVIA-CDM, IQVIA-Core Diabetes Model; T2DM, type 2 diabetes mellitus; UKPDS, UK Prospective Diabetes Study; UKPDS-OM, UKPDS Outcomes Model.](nihms-1037199-f0002){#F2}

###### 

Average cost reductions per individual in the UK T2DM population estimated from the Baxter et al. \[[@R13]\] study and by participating modeling groups.

  Baseline HbA1c                                Baxter study   Participating modeling groups                  
  --------------------------------------------- -------------- ------------------------------- ------- ------ -------
  \< 59 mmol/mol (7.5%)                                                                                       
   5 y                                          £83            £16                             £154    £7     £13
   10 y                                         £317           £73                             £418    £174   £151
   15 y                                         £682           £179                            £644    £353   £605
   20 y                                         £1078          £307                            £838    £484   £1283
   25 y                                         £1280          £422                            £911    £521   £1799
  \>59 mmol/mol (7.5%) to 64 mmol/mol (8.0%)                                                                  
   5 y                                          £132           £26                             £170    £60    £9
   10 y                                         £449           £104                            £457    £208   £317
   15 y                                         £995           £235                            £658    £337   £1069
   20 y                                         £1510          £385                            £860    £379   £1906
   25 y                                         £1678          £518                            £976    £324   £2503
  \> 64 mmol/mol (8.0%) to 75 mmol/mol (9.0%)                                                                 
   5 y                                          £138           £68                             £157    £83    −£16
   10 y                                         £607           £201                            £412    £218   £294
   15 y                                         £1366          £384                            £651    £329   £1198
   20 y                                         £1999          £580                            £869    £331   £2440
   25 y                                         £2223          £748                            £942    £236   £3810
  \> 75 mmol/mol (9.0%)                                                                                       
   5 y                                          £105           £160                            £150    £146   £169
   10 y                                         £622           £402                            £427    £372   £1019
   15 y                                         £1274          £697                            £750    £561   £2442
   20 y                                         £1591          £993                            £923    £584   £4255
   25 y                                         £1559          £1231                           £1088   £476   £5590

ECHO-T2DM, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc.---Treatment Transitions Model; IQVIA-CDM, IQVIA-CORE Diabetes Model; T2DM, type 2 diabetes mellitus.

###### 

Total complications avoided in the UK T2DM population estimated from the Baxter et al. \[[@R13]\] study and by participating modeling groups.

  Complications                              Baxter study   Participating modeling groups                          
  ------------------------------------------ -------------- ------------------------------- ---------- ----------- -----------
  Eye disease                                                                                                      
   5 y                                         56,777       12,046                          403,839      5,045     19,530
   10 y                                      141,792        19,764                          684,490    15,825      129,321
   15 y                                      224,992        26,477                          837,948    27,536      269,037
   20 y                                      261,069        31,865                          898,574    34,382      399,513
   25 y                                      250,768        34,701                          942,337    36,514      456,766
  Renal disease                                                                                                    
   5 y                                         38,151         25                              14,712     1,652       13,489
   10 y                                        95,975         40                              26,794     3,724       77,000
   15 y                                      152,114          47                              35,785     −1,982    164,851
   20 y                                      174,601          52                              41,835   −14,083     255,038
   25 y                                      164,187          59                              47,992   −27,836     294,751
  Foot ulcers, amputations, and neuropathy                                                                         
   5y                                        122,013        15,847                            78,367       3,934       9,343
   10 y                                      275,011        27,678                          163,711      15,975    162,908
   15 y                                      389,723        35,548                          229,138      33,422    286,712
   20 y                                      412,535        43,458                          265,308      47,265    354,630
   25 y                                      373,629        49,324                          292,704      54,802    347,470
  Cardiovascular disease                                                                                           
   5y                                          27,991         23,124                          46,472     13,303        5,569
   10 y                                        61,893         50,804                          97,207     40,358      40,431
   15 y                                        97,890       115,335                         132,514      64,231      91,852
   20 y                                      106,416          92,475                        147,792      73,479    146,743
   25 y                                        82,387       112,709                         149,673      68,224    168,866

ECHO, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc.---Treatment Transitions Model; IQVIA-CDM, IQVIA-CORE Diabetes Model; T2DM, type 2 diabetes mellitus.

###### 

Undiscounted within - trial total costs and total QALYs as well as differences for conventional vs. intensive blood glucose control estimated from the UKPDS 72 \[[@R14]\] and other modeling groups.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Simulation\                                     UKPDS\   Participating modeling groups                                                
  outcomes                                        72                                                                                    
  ----------------------------------------------- -------- ------------------------------- -------- -------- -------- -------- -------- --------
  Total costs^[\*](#TFN4){ref-type="table-fn"}^                                                                                         

   Conventional                                   26,516   26,996                          14,806   13,094   13,288   34,523   21,154   19,428

   Intensive                                      27,865   28,936                          16,733   13,529   14,366   32,986   23,121   21,689

  *Differences in total cost*                     1,349    1,940                           1,927    435      1,078    −1,537   1,967    2,261

  Within-trial QALYs                                                                                                                    

   Conventional                                   7.62     7.64                            7.96     6.94     NR       7.27     NR       NR

   Intensive                                      7.72     7.67                            7.99     6.96     NR       7.32     NR       NR

  *Differences in within-trial QALYs*             0.10     0.03                            0.03     0.02     NR       0.05     NR       NR

  Total QALYs                                                                                                                           

   Conventional                                   16.35    17.23                           15.94    16.75    9.22     18.13    16.59    19.14

   Intensive                                      16.62    17.47                           16.11    16.94    9.50     18.45    16.79    19.29

  *Differences in total QALYs*                    0.27     0.24                            1.17     0.19     0.28     0.32     0.20     0.15
  ----------------------------------------------------------------------------------------------------------------------------------------------

ECHO, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc.---Treatment Transitions Model; MICADO, Modelling Integrated Care for Diabetes based on Observational data; NR, not reported; QALY, quality-adjusted life-year; IQVIA-CDM, IQVIA-CORE Diabetes Model; T2DM, type 2 diabetes mellitus; UKPDS, UK Prospective Diabetes Study; UKPDS-OM, UKPDS Outcomes Model.

Costs are presented in 2004 British pounds.

###### 

Checklist of reporting model input in diabetes health economics studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model input                                                                                                                                                                                                           Checkbox   Comments\
                                                                                                                                                                                                                                   (e.g., justification\
                                                                                                                                                                                                                                   if not reported)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- -----------------------
  Simulation cohort                                                                                                                                                                                                                

   Baseline age                                                                                                                                                                                                                    

   Ethnicity/race                                                                                                                                                                                                                  

   BMI/weight                                                                                                                                                                                                                      

   Duration of diabetes                                                                                                                                                                                                            

   Baseline HbA~1C~, lipids, and blood pressure                                                                                                                                                                                    

   Smoking status                                                                                                                                                                                                                  

   Comorbidities                                                                                                                                                                                                                   

   Physical activity                                                                                                                                                                                                               

   Baseline treatment                                                                                                                                                                                                              

  Treatment intervention                                                                                                                                                                                                           

   Type of treatment                                                                                                                                                                                                               

   Treatment algorithm for HbA~1c~ evolution over time                                                                                                                                                                             

   Treatment algorithm for other conditions (e.g., hypertension, dyslipidemia, and excess weight)                                                                                                                                  

   Treatment initial effects on baseline biomarkers                                                                                                                                                                                

   Rules for treatment intensification (e.g., the cutoff HbA~1C~ level to switch the treatment, the type of new treatment, and whether the rescue treatment is an addition or substitution to the standard treatment)              

   Long-term effects, adverse effects, treatment adherence and persistence, and residual effects after the discontinuation of the treatment                                                                                        

   Trajectory of biomarkers, BMI, smoking, and any other factors that are affected by treatment Cost                                                                                                                               

   Differentiated by acute event in first year and subsequent years                                                                                                                                                                

   Cost of intervention and other costs (e.g., managing complications, adverse events, and diagnostics)                                                                                                                            

   Please report unit prices and resource use separately and give information on discount rates applied                                                                                                                            

  Health state utilities                                                                                                                                                                                                           

   Operational mechanics of the assignment of utility values (i.e., utility- or disutility-oriented)                                                                                                                               

   Management of multihealth conditions                                                                                                                                                                                            

  General model characteristics                                                                                                                                                                                                    

   Choice of mortality table and any specific event-related mortality                                                                                                                                                              

   Choice and source of risk equations                                                                                                                                                                                             

   If microsimulation: number of Monte-Carlo simulations conducted and justification                                                                                                                                               

   Components of model uncertainty being simulated (e.g., risk equations, risk factor trajectories, costs, and treatment effect); number of simulations and justification                                                          

  BMI, body mass index; HbA~1c~, glycated hemoglobin.                                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
